Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia
- 8 July 2019
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 25 (5) , 738-746
Abstract
Gene therapy is rapidly becoming a new therapeutic strategy for haemophilia A and B treatment. In the 1990s, studies in animal models showed that adeno‐associated vectors (AAV) exhibited an efficient expression of factor IX (FIX). In the first clinical trial in patients with haemophilia B, therapeutic levels of FIX were documented but the expression remained only for few weeks. Subsequently, improvements in vector design, such as the use of different AAV serotypes, the development of the self‐complementary vector, the engineering of the transgene with codon optimization and liver‐specific expression cassette resulted in circulating FIX level between 2% and 5% for long‐lasting period. Recently, a natural gain of function FIX variant (Padua) inserted in the F9 cDNA improved the expression of FIX achieving a level of more than 30% resulting in cessation of infusions and in a greatly reduction of bleeding events. Encouraging clinical progresses have been also obtained from trials of gene therapy for haemophilia A. Transgene expression persisted for three years with circulating FVIII activity levels of 52.3% in patients treated with AAV vector containing a codon‐optimized F8 cDNA. A complication, reported in both clinical trials for haemophilia A and B, was the elevation of liver enzymes, which resolved with steroid treatment in a large group of patients. However, to date, the pathophysiological mechanism for the liver toxicity remains still unclear. Clinical trials with adeno‐associated vectors have documented a significant success for haemophilia gene therapy demonstrating potential to transform haemophilia treatment offering hope for a long‐term expression.Keywords
This publication has 54 references indexed in Scilit:
- The AAV Vector Toolkit: Poised at the Clinical CrossroadsMolecular Therapy, 2012
- Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transferBlood, 2012
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challengesExpert Review of Hematology, 2011
- Codon optimization of human factor VIII cDNAs leads to high-level expressionBlood, 2011
- Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene TherapyMolecular Therapy, 2010
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010
- Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kbMolecular Therapy, 2010
- Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate MuscleJournal of Virology, 2008
- Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primatesBlood, 2006